Brief: Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation
06/03/2025 24:52
March 6 (Reuters) - Ascentage Pharma Group International 6855.HK: OLVEREMBATINIB GIVEN BREAKTHROUGH THERAPY DESIGNATION BY CENTER FOR DRUG EVALUATION OF CHINA NMPA Further company coverage: 6855.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up